206 related articles for article (PubMed ID: 19826406)
1. Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.
Busser B; Sancey L; Josserand V; Niang C; Favrot MC; Coll JL; Hurbin A
Mol Ther; 2010 Mar; 18(3):528-35. PubMed ID: 19826406
[TBL] [Abstract][Full Text] [Related]
2. Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation.
Busser B; Sancey L; Josserand V; Niang C; Khochbin S; Favrot MC; Coll JL; Hurbin A
Mol Ther; 2010 Mar; 18(3):536-43. PubMed ID: 19826407
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
Hurbin A; Wislez M; Busser B; Antoine M; Tenaud C; Rabbe N; Dufort S; de Fraipont F; Moro-Sibilot D; Cadranel J; Coll JL; Brambilla E
J Pathol; 2011 Sep; 225(1):83-95. PubMed ID: 21598249
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines.
Hurbin A; Dubrez L; Coll JL; Favrot MC
J Biol Chem; 2002 Dec; 277(51):49127-33. PubMed ID: 12356750
[TBL] [Abstract][Full Text] [Related]
5. [Effection and mechanism of radiosensitivity of non-small cell lung cancer cell line H358 following gefitinib treatment].
Deng J; Zhuang L; Chen Y
Zhongguo Fei Ai Za Zhi; 2011 Nov; 14(11):841-7. PubMed ID: 22104217
[TBL] [Abstract][Full Text] [Related]
6. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA
Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
[TBL] [Abstract][Full Text] [Related]
8. Cooperation of amphiregulin and insulin-like growth factor-1 inhibits Bax- and Bad-mediated apoptosis via a protein kinase C-dependent pathway in non-small cell lung cancer cells.
Hurbin A; Coll JL; Dubrez-Daloz L; Mari B; Auberger P; Brambilla C; Favrot MC
J Biol Chem; 2005 May; 280(20):19757-67. PubMed ID: 15767261
[TBL] [Abstract][Full Text] [Related]
9. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
10. TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription.
Yuan W; Xu W; Li Y; Jiang W; Li Y; Huang Q; Chen B; Wu S; Wang Y; Song W; Zhao W; Wu J
Cell Death Dis; 2019 Mar; 10(4):283. PubMed ID: 30911072
[TBL] [Abstract][Full Text] [Related]
11. TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non-small-cell lung cancer.
Shuai S; Liao X; Wang H; Liu L; Mei S; Cao J; Wang S
Cancer Sci; 2021 Oct; 112(10):4139-4150. PubMed ID: 34058054
[TBL] [Abstract][Full Text] [Related]
12. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
14. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.
Oliveras-Ferraros C; Cufí S; Queralt B; Vazquez-Martin A; Martin-Castillo B; de Llorens R; Bosch-Barrera J; Brunet J; Menendez JA
Br J Cancer; 2012 Apr; 106(8):1406-14. PubMed ID: 22491422
[TBL] [Abstract][Full Text] [Related]
15. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
[TBL] [Abstract][Full Text] [Related]
16. The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop.
Wang X; Masri S; Phung S; Chen S
Cancer Res; 2008 Apr; 68(7):2259-65. PubMed ID: 18381432
[TBL] [Abstract][Full Text] [Related]
17. Restricting extracellular Ca2+ on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca2+ response, which consequently enhances gefitinib sensitivity.
Kim MS; Kim SH; Yang SH; Kim MS
PLoS One; 2020; 15(8):e0238155. PubMed ID: 32841278
[TBL] [Abstract][Full Text] [Related]
18. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
[TBL] [Abstract][Full Text] [Related]
19. RAGE potentiates EGFR signaling and interferes with the anticancer effect of gefitinib on NSCLC cells.
Liao WL; Lin H; Li YH; Yang TY; Chen MC
Am J Physiol Cell Physiol; 2023 Nov; 325(5):C1313-C1325. PubMed ID: 37746694
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice.
Lorch G; Gilmore JL; Koltz PF; Gonterman RM; Laughner R; Lewis DA; Konger RL; Nadella KS; Toribio RE; Rosol TJ; Foley J
Br J Cancer; 2007 Jul; 97(2):183-93. PubMed ID: 17533397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
